Avastin
E46087
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
All labels observed (3)
| Label | Occurrences |
|---|---|
| bevacizumab | 3 |
| Avastin canonical | 2 |
| VEGF-A | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T363282 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Avastin Context triple: [Genentech, notableProduct, Avastin]
-
A.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
C.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
D.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Avastin Target entity description: Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
A.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
B.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
C.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
D.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
anti‑angiogenic agent
ⓘ
biologic medicinal product ⓘ drug ⓘ monoclonal antibody ⓘ |
| antibodyIsotype | IgG1 ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| belongsToCompanyPortfolio | Roche oncology portfolio ⓘ |
| commonAdverseEffect |
hemorrhage
ⓘ
hypertension ⓘ proteinuria ⓘ |
| contraindication |
recent major surgery
ⓘ
uncontrolled hypertension ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| FDAApprovalYear | 2004 ⓘ |
| hasATCCode | L01FG01 ⓘ |
| hasDrugClass |
VEGF inhibitor
ⓘ
angiogenesis inhibitor ⓘ antineoplastic agent ⓘ |
| hasGenericName | bevacizumab ⓘ |
| hasINN |
bevacizumab
ⓘ
linked to:
Avastin
|
| indicationType | oncology ⓘ |
| isBrandOf |
bevacizumab
ⓘ
linked to:
Avastin
|
| isMonoclonalAntibodyType | humanized monoclonal antibody ⓘ |
| legalStatus | prescription only ⓘ |
| manufacturer |
Genentech
ⓘ
Roche ⓘ |
| mechanismOfAction |
inhibits angiogenesis by binding VEGF-A
ⓘ
prevents VEGF-A from binding to its receptors on endothelial cells ⓘ |
| oftenUsedInCombinationWith |
chemotherapy
ⓘ
fluorouracil‑based regimens ⓘ |
| origin | recombinant DNA technology ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| seriousAdverseEffect |
arterial thromboembolic events
ⓘ
gastrointestinal perforation ⓘ wound healing complications ⓘ |
| targets |
VEGF-A
ⓘ
linked to:
Avastin
vascular endothelial growth factor A ⓘ |
| usedForTreatmentOf |
cervical cancer
ⓘ
epithelial ovarian cancer ⓘ fallopian tube cancer ⓘ glioblastoma ⓘ hepatocellular carcinoma (in combination regimens) ⓘ metastatic colorectal cancer ⓘ non‑small cell lung cancer ⓘ primary peritoneal cancer ⓘ renal cell carcinoma ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Avastin Description of subject: Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.